IL-6 BLOCKADE WITH TOCILIZUMAB: EMERGING HORIZONS IN CONNECTIVE TISSUE DISEASE MANAGEMENT
Main Article Content
Keywords
..............
Abstract
Interleukin-6 (IL-6) is a key pleiotropic cytokine involved in immune regulation, inflammation, and fibrosis, playing a central role in the pathogenesis of several connective tissue diseases (CTDs). Tocilizumab, a humanized monoclonal antibody targeting both soluble and membrane-bound IL-6 receptors, has emerged as an important therapeutic agent across a spectrum of immune-mediated disorders. This narrative review summarizes the mechanism of action, pharmacokinetics, and clinical efficacy of tocilizumab in major connective tissue and related inflammatory diseases.
Tocilizumab inhibits IL-6–mediated classical and trans-signaling pathways, resulting in suppression of downstream JAK-STAT and MAPK signaling, reduction of acute-phase reactants, and modulation of adaptive immune responses. Pharmacokinetic properties are characterized by nonlinear, dose-dependent clearance and a terminal half-life of 8–14 days, with clinically relevant effects on cytochrome P450 metabolism.Clinical evidence supporting tocilizumab varies across disease entities. Robust efficacy has been demonstrated in giant cell arteritis and multicentric Castleman disease, where randomized controlled trials show sustained remission and significant glucocorticoid-sparing effects. In systemic sclerosis, particularly systemic sclerosis–associated interstitial lung disease, tocilizumab has shown consistent preservation of lung function, leading to regulatory approval in selected populations. Moderate evidence supports its use in adult-onset Still’s disease and refractory Takayasu arteritis. In contrast, randomized trials in systemic lupus erythematosus, primary Sjögren’s syndrome, and idiopathic inflammatory myopathies have yielded limited or negative results, restricting its use to experimental or highly selected refractory cases. Overall, tocilizumab represents a targeted, disease-modifying therapy with variable efficacy across connective tissue diseases. Optimal patient selection and further biomarker-driven trials are essential to refine its role in conditions with heterogeneous clinical responses.
References
2. Kishimoto T. Interleukin-6: from basic science to medicine—40 years in immunology. Blood. 2005;106(7):2243–2249. doi:10.1182/blood-2005-02-0842.
3. Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13(7):399–409. doi:10.1038/nrrheum.2017.83.
4. European Medicines Agency (EMA). RoActemra® (tocilizumab): Summary of Product Characteristics. Amsterdam: EMA; 2023.
5. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease–drug–drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735–740. doi:10.1038/clpt.2011.38.
6. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Arthritis Rheum. 2004;50(9):2751–2760. doi:10.1002/art.20453.
7. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–552. doi:10.1002/art.27221.
8. Mavragani CP, Fragoulis GE, Moutsopoulos HM. Cytokines in Sjögren’s syndrome: IL-6 and beyond. J Autoimmun. 2010;35(3):199–205. doi:10.1016/j.jaut.2010.06.015.
9. Felten R, Ravaud P, Mariette X, Berenbaum F, Gottenberg JE, Salliot C, et al. Interleukin-6 receptor inhibition in primary Sjögren’s syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2021;80(3):329–338. doi:10.1136/annrheumdis-2020-218467.
10. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9.
11. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630–2640. doi:10.1016/S0140-6736(16)00232-4.
12. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al.; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. N Engl J Med. 2020;382(23):2238–2249. doi:10.1056/NEJMoa1919845.
13. Roofeh D, Lin CJF, Goldin J, Kim GHJ, Furst DE, Denton CP, et al. Tocilizumab prevents progression of early systemic sclerosis–associated interstitial lung disease. Arthritis Rheumatol. 2021;73(7):1301–1310. doi:10.1002/art.41668.
14. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Cytokine expression in idiopathic inflammatory myopathies. Cytokine. 2002;18(5):235–241. doi:10.1006/cyto.2002.0896.
15. Oddis CV, Reed AM, Aggarwal R, Koontz DC, Fertig N, Catlett J, et al. Tocilizumab in patients with refractory polymyositis and dermatomyositis: a randomized, double-blind, placebo-controlled phase 2B study. Arthritis Rheumatol. 2022;74(7):1160–1170. doi:10.1002/art.42045.
16. Li S, Sun Y, Shao X, Zhang L, Wang Q. The efficacy and safety of tocilizumab in idiopathic inflammatory myopathies: a systematic review. Front Pharmacol. 2021;12:786485. doi:10.3389/fphar.2021.786485.
17. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. doi:10.1056/NEJMoa1613849.
18. Calderón-Goercke M, Loricera J, Aldasoro V, Villa I, Humbría A, González-Gay MA. Long-term tocilizumab therapy in giant cell arteritis: clinical outcomes and safety. Rheumatology (Oxford). 2024;63(1):123–132. doi:10.1093/rheumatology/kead410.
19. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919–929. doi:10.7326/0003-4819-120-11-199406010-00004.
20. Nakaoka Y, Isobe M, Takeuchi T, Tanaka Y, Yokota S, Tanaka F, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomized, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(3):348–354. doi:10.1136/annrheumdis-2017-211878.
21. Mekinian A, Resche-Rigon M, Comarmond C, Mirault T, Kahn JE, Lambert M, et al. Efficacy of tocilizumab in Takayasu arteritis: multicenter retrospective study of 46 patients. Autoimmun Rev. 2020;19(2):102517. doi:10.1016/j.autrev.2019.102517.
22. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13(7):708–722. doi:10.1016/j.autrev.2014.01.058.
23. Kaneko Y, Kameda H, Ikeda K, Yamaoka K, Takeuchi T. Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid therapy: a randomized, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720–1729. doi:10.1136/annrheumdis-2018-213820.
24. Sota J, Vitale A, Rigante D, Lopalco G, Franceschini R, Emmi G, et al. Efficacy and safety of tocilizumab in adult-onset Still’s disease: a multicenter retrospective study. Clin Exp Rheumatol. 2022;40(6):1123–1131.
25. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646–1657. doi:10.1182/blood-2016-10-746933.
26. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–2632. doi:10.1182/blood-2005-03-1108.
27. Nishimoto N, Honda O, Sumikawa H, Johkoh T, Aozasa K, Kanakura Y. Long-term (5-year) sustained efficacy of tocilizumab for multicentric Castleman’s disease. Blood. 2007;110(11):646.
28. Mariette X, Criswell LA. Primary Sjögren’s syndrome. N Engl J Med. 2018;378(10):931–939. doi:10.1056/NEJMcp1702514.
29. Sota J, Vitale A, Rigante D, Lopalco G, Franceschini R, Emmi G, et al. Efficacy and safety of tocilizumab in adult-onset Still’s disease: a multicenter retrospective study. Clin Exp Rheumatol. 2022;40(6):1123–1131.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Balakrishnan Navaneethakrishnan
Consultant Rheumatologist, Avinash hospitals, Chennai, Tamil Nadu, India.
Dr Mahabaleshwar Mamadapur
Assistant Professor, Department of Clinical Immunology and Rheumatology, JSS Medical College, JSS Academy of Higher Research, Mysuru
Dr Sabarinath Mahadevan
Assistant Professor, Institute of Rheumatology, Madras Medical College, Chennai, Tamil Nadu
